The management of orphan drug prices after loss of exclusivity
What happens to orphan drugs when they lose market exclusivity? Do they face generic competition and price reductions like other drugs? Post by Ischa Bruinsma, Consultant The Dutch National Health Care Institute (Zorginstituut Nederland, ZIN) has recently published a report on research conducted on the prices and costs of reimbursed orphan drugs in the Netherlands. The report, titled “Monitor Orphan Drugs in Practice in 2020”, concluded that total expenditure for orphan drugs